Last reviewed · How we verify
NCT03732014
Bronchial Washings in Sputum Scarce Cases of Pulmonary Tuberculosis
trial in Tuberculosis, Pulmonary. Withdrawn.
1 September 2019
Quick facts
| Lead sponsor | Faisal Faiyaz Zuberi |
|---|---|
| Status | Withdrawn |
| Study type | OBSERVATIONAL |
| Start date | 2 January 2019 |
| Primary completion | 1 September 2019 |
| Estimated completion | 30 November 2019 |
| Sites | 1 location across Pakistan |
Conditions studied
- Tuberculosis, Pulmonary — all drugs for Tuberculosis, Pulmonary →
Sponsor
Faisal Faiyaz Zuberi
Who can join
Adults 12 to 70, any sex, with Tuberculosis, Pulmonary. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will be conducted in Ojha Institute of Chest Diseases and Department of Medicine, Dow Medical College, Karachi both affiliated with Dow University of Health Sciences, Karachi, Pakistan after IRB approval. All patients of either gender with clinical suspicion of PTB on history, examination and CXR and not expectorating sputum or less than 1 ml will be included in the study. Patients with extra pulmonary tuberculosis, those with age \< 12 years will be excluded. Demographic data of selected patients including age, gender, contact with PTB patient will be collected. Data will be entered in study proforma. Selected patients will undergo bronchoscopy using Olympus 180 series video bronchoscope. Bronchial Wash will be done and 3 aliquots of BW samples will be collected by suctioning. One part of washing will be immediately inoculated in AFB Culture media and second will be submitted for Xpert MTB/RIF testing. Third part will be centrifuged, and sediment will be subjected to AFB microscopy after staining with Ziehl-Neelsen technique. Results of microscopy and Xpert MTB/RIF will be collected next day, and treatment will be started if MTB comes positive, while results of AFB Culture will be collected after 6 weeks and treatment will be started if not already started on previous reports. Sensitivity/Resistance pattern will be recorded for both Xpert MTB/RIF and ABF Culture. The sample size of 72 was taken for conduct of study. Sample size calculations were done using PASS software version 15.0. Frequency of positive tests will be calculated. Mean age will be calculated according to gender and compared by Student's t-test. Sensitivity \& specificity of tests will be calculated using online calculator by VassarStats. Frequency of positive yield of Xpert MTB/RIF will be compared to that of microscopy by χ2- test. P-value of \<0.05 was considered significant.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03732014
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Tuberculosis, Pulmonary
Currently open trials in the same condition.
- NCT07077213 — 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients · recruiting
- NCT07271225 — Safety and Efficacy of Ear Acupuncture for Antituberculosis Drug-Related Nausea and Vomiting · NA · recruiting
- NCT06845618 — Blood Tuberculosis DNA Levels to Monitor Tuberculosis Treatment · recruiting
- NCT06253715 — Shortened Regimen for Drug-susceptible TB in Children · Phase 3 · recruiting
- NCT06057519 — Pragmatic Optimized Rifampicin Trial · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03732014 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Faisal Faiyaz Zuberi
- Last refreshed: 23 August 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03732014.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing